The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2021 | MagnetisMM-3: elranatamab for myeloma
Alexander Lesokhin, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the MagnetisMM-3 trial (NCT04649359), a study investigating whether single-agent elranatamab (PF-06863135) can provide clinical benefit in patients with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody that binds to two antigens, CD3 on T-cells and B-cell maturation antigen (BCMA). By bringing T-cells and cancer cells in close proximity, elranatamab can activate the T-cell killing of myeloma cells. This interview took place during the 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA.
